Immix Biopharma (IMMX) priced an underwritten public offering of 16.8 million shares of common stock at $8.94 per share, raising expected gross proceeds of about $150 million, the company said Thursday.
Proceeds from the offering will fund NXC-201 development, working capital, and general corporate purposes, and together with existing cash, support operations into mid-2028, the company said.
The offering is expected to close Friday, the company added.
Immix Biopharma shares were up 9.7% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments